Beerse, Belgium (ots/PRNewswire) - FOR UK AND EMEA MEDICAL MEDIA ONLY Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a change to the terms of the marketing ...
Beerse, Belgium (ots/PRNewswire) - - First and Only Biologic Approved With Infrequent, Every Twelve-Week Maintenance Dosing BEERSE, Belgium, January 22 /PRNewswire/ -- Janssen-Cilag announced today that STELARA(TM) (ustekinumab), the first in a new class of biologics, has been approved by the ...
Beerse, Belgium (ots/PRNewswire) - - Preliminary Phase II Re-treatment Results and two new Analyses From Phase III VISTA Presented at ASH Annual Meeting Janssen-Cilag today announced preliminary results from a prospective, international, multicenter, open-label, phase II study showing re-treatment with ...
Beerse, Belgium, November 21 (ots/PRNewswire) - - European Authority Recommends Approval of ZEVTERA(TM) BEERSE, Belgium, November 21 /PRNewswire/ -- - A Broad-spectrum, Anti-MRSA Cephalosporin Antibiotic to Treat Complicated Skin and Soft Tissue Infections BEERSE, Belgium, November 21 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the antibiotic, ...
Beerse, Belgium, November 21 (ots/PRNewswire) - Janssen-Cilag announced today that ustekinumab, the first in a new class of biologics, has received a positive opinion for the treatment of moderate to severe plaque psoriasis from the European Committee for Medical Products for Human Use (CHMP). This positive ...
Baar, Switzerland, November 13 (ots/PRNewswire) - - ZEVTERA(TM) A Broad-spectrum, Anti-MRSA Cephalosporin Antibiotic to Treat Complicated Skin and Soft Tissue Infections Approved in Switzerland - Not for UK Media Swissmedic, the Swiss agency for therapeutic products, has approved ZEVTERA(TM) (ceftobiprole medocaril) for the treatment of complicated skin ...
Beerse, Belgium (ots/PRNewswire) - Today, Janssen-Cilag are celebrating their 50 year commitment to researching and developing innovative medicines to help improve the lives of people with mental health problems. Back in 1958, the late Dr. Paul Janssen developed one of the first anti-psychotic drugs, which proved to be a real breakthrough in the treatment of schizophrenia and hailed the onset of a new era for patients ...
San Antonio, Texas (ots/PRNewswire) - - New Findings From a Second Pivotal Phase 3 Study Show Subjects Receiving Ustekinumab Every 12 weeks Maintained Improvement From Psoriasis Through One Year One-year data from the second double blind, placebo-controlled Phase 3 study PHOENIX 1 showed therapy with ...
Beerse, Belgium (ots/PRNewswire) - Janssen-Cilag International NV announced today that the European Medicines Agency (EMEA) has accepted for review a Marketing Authorization Application (MAA) for doripenem, an investigational carbapenem antibiotic for the treatment of nosocomial pneumonia (NP), including ...
Beerse, Belgium (ots/PRNewswire) - Janssen-Cilag International NV has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for ceftobiprole, an investigational antibiotic for the treatment of complicated skin and soft tissue infections (cSSTI) including diabetic foot ...